{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:18:35Z","timestamp":1771845515704,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen Australia- unrestricted investigator initiated research grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0910-9","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T03:56:16Z","timestamp":1526356576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism"],"prefix":"10.1186","volume":"19","author":[{"given":"Irene","family":"Ruderman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel D.","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim D.","family":"Hewitson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"910_CR1","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009(113):S1\u2013130."},{"issue":"2","key":"910_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1525-139X.2003.160301.x","volume":"16","author":"G Block","year":"2003","unstructured":"Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial. 2003;16(2):140\u20137.","journal-title":"Semin Dial"},{"issue":"1","key":"910_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","volume":"14","author":"SM Moe","year":"2007","unstructured":"Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14(1):3\u201312.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"910_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1525-139X.2009.00581.x","volume":"22","author":"M Rodriguez","year":"2009","unstructured":"Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial. 2009;22(4):363\u20138.","journal-title":"Semin Dial"},{"issue":"Suppl 10","key":"910_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ndt\/17.suppl_10.2","volume":"17","author":"M Fukagawa","year":"2002","unstructured":"Fukagawa M, Kazama JJ, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17(Suppl 10):2\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"910_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/CIA.S38856","volume":"8","author":"A Fisher","year":"2013","unstructured":"Fisher A, Srikusalanukul W, Davis M, Smith P. Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging. 2013;8:239\u201356.","journal-title":"Clin Interv Aging"},{"issue":"6","key":"910_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/ki.1987.293","volume":"32","author":"GM London","year":"1987","unstructured":"London GM, De Vernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, London AM, Llach F. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int. 1987;32(6):900\u20137.","journal-title":"Kidney Int"},{"issue":"3","key":"910_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/ki.1990.58","volume":"37","author":"M Akmal","year":"1990","unstructured":"Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37(3):854\u20138.","journal-title":"Kidney Int"},{"issue":"10","key":"910_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM197503062921003","volume":"292","author":"K Yasuda","year":"1975","unstructured":"Yasuda K, Hurukawa Y, Okuyama M, Kikuchi M, Yoshinaga K. Glucose tolerance and insulin secretion in patients with parathyroid disorders. N Engl J Med. 1975;292(10):501\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"910_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/01.RES.0000141775.67189.98","volume":"95","author":"SM Moe","year":"2004","unstructured":"Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95(6):560\u20137.","journal-title":"Circ Res"},{"issue":"2","key":"910_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1054-8807(03)00130-3","volume":"13","author":"MY Speer","year":"2004","unstructured":"Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol. 2004;13(2):63\u201370.","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"910_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCRESAHA.111.261479","volume":"111","author":"M Herrmann","year":"2012","unstructured":"Herrmann M, Schafer C, Heiss A, Graber S, Kinkeldey A, Buscher A, Schmitt MM, Bornemann J, Nimmerjahn F, Herrmann M, et al. Clearance of fetuin-A--containing calciprotein particles is mediated by scavenger receptor-a. Circ Res. 2012;111(5):575\u201384.","journal-title":"Circ Res"},{"issue":"10","key":"910_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/ndt\/gfw048","volume":"31","author":"SG Holt","year":"2016","unstructured":"Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrol Dial Transplant. 2016;31(10):1583\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"910_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bone.2018.02.023","volume":"110","author":"ER Smith","year":"2018","unstructured":"Smith ER, Hewitson TD, Hanssen E, Holt SG. Biochemical transformation of calciprotein particles in uraemia. Bone. 2018;110:355\u201367.","journal-title":"Bone"},{"issue":"1","key":"910_CR15","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1038\/s41598-017-05474-y","volume":"7","author":"ER Smith","year":"2017","unstructured":"Smith ER, Hewitson TD, Cai MMX, Aghagolzadeh P, Bachtler M, Pasch A, Holt SG. A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci Rep. 2017;7(1):5686.","journal-title":"Sci Rep"},{"issue":"3","key":"910_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/nep.12021","volume":"18","author":"ER Smith","year":"2013","unstructured":"Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG. Serum fetuin-a concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology. 2013;18(3):215\u201321.","journal-title":"Nephrology"},{"issue":"2","key":"910_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1681\/ASN.2013060635","volume":"25","author":"ER Smith","year":"2014","unstructured":"Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG, Pasch A. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol. 2014;25(2):339\u201348.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"910_CR18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/ndt\/gfr609","volume":"27","author":"ER Smith","year":"2012","unstructured":"Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012;27(5):1957\u201366.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"910_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/nep.12137","volume":"18","author":"MM Cai","year":"2013","unstructured":"Cai MM, Smith ER, Brumby C, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particle levels can be reduced by dialysis, sodium thiosulphate and plasma exchange. Potential therapeutic implications for calciphylaxis? Nephrology. 2013;18(11):724\u20137.","journal-title":"Nephrology"},{"issue":"11","key":"910_CR20","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1681\/ASN.2009090944","volume":"21","author":"T Hamano","year":"2010","unstructured":"Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010;21(11):1998\u20132007.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"910_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327\u201339.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"910_CR22","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(8):3270\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"910_CR23","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"Investigators TET","year":"2012","unstructured":"Investigators TET. Effect of Cinacalcet on cardiovascular disease in patients undergoing Dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"3","key":"910_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2215\/CJN.06370615","volume":"11","author":"PS Parfrey","year":"2016","unstructured":"Parfrey PS, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM. Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin J Am Soc Nephrol. 2016;11(3):539\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"key":"910_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2215\/CJN.01760215","volume":"11","author":"J Bover","year":"2016","unstructured":"Bover J, Urena P, Ruiz-Garcia C, da Silva I, Lescano P, del Carpio J, Ballarin J, Cozzolino M. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2016;11:161\u201374.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"910_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/MNH.0000000000000237","volume":"25","author":"A Pasch","year":"2016","unstructured":"Pasch A. Novel assessments of systemic calcification propensity. Curr Opin Nephrol Hypertens. 2016;25(4):278\u201384.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"910_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00109-007-0294-y","volume":"86","author":"W Jahnen-Dechent","year":"2008","unstructured":"Jahnen-Dechent W, Schafer C, Ketteler M, McKee MD. Mineral chaperones: a role for fetuin-a and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008;86(4):379\u201389.","journal-title":"J Mol Med"},{"issue":"9","key":"910_CR28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/ki.2008.700","volume":"75","author":"I Matsui","year":"2009","unstructured":"Matsui I, Hamano T, Mikami S, Fujii N, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Rakugi H, Imai E, Isaka Y. Fully phosphorylated fetuin-a forms a mineral complex in the serum of rats with adenine-induced renal failure. Kidney Int. 2009;75(9):915\u201328.","journal-title":"Kidney Int"},{"key":"910_CR29","volume-title":"39th report, chapter 3: mortality in end stage kidney disease","author":"ANZDATA Registry","year":"2017","unstructured":"ANZDATA Registry. 39th report, chapter 3: mortality in end stage kidney disease. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2017. Available at: \n                    http:\/\/www.anzdata.org.au"},{"key":"910_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1359\/jbmr.2002.17.7.1171","volume":"17","author":"PA Price","year":"2002","unstructured":"Price PA, Caputo JM, Williamson MK. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res. 2002;17:1171\u20139.","journal-title":"J Bone Miner Res"},{"key":"910_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2016.05.044","volume":"251","author":"P Aghagolzadeh","year":"2016","unstructured":"Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis. 2016;251:404\u201314.","journal-title":"Atherosclerosis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-0910-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:10:07Z","timestamp":1557861007000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0910-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0910-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research performed in accordance with the Declaration of Helsinki. The study was approved by the Melbourne Health Human Research Ethics Committee (#HREC 2015.180). Written informed consent was obtained from all participants at study commencement.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ERS owns stock in Calciscon. ERS received research funding from Amgen, Baxter and Sanofi. NDT has received honoraria, travel support and research funding from Amgen, Shire and Sanofi. SGH has research funding, honoraria, travel support and from Amgen, Astra-Zenica, Baxter and Sanofi. TDH and IR declares that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"113"}}